Global Keratolytic Agents Market Research Report 2023

Publication ID:

PB502230195

Publication Date:

February 27, 2023

Pages:

102

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

Keratolytic agents are the type of compounds which break down the outer layer of skin and minimize the thickness of skin damage cells with the help of exfoliation. These agents are applied to soften the skin and is useful in treating several dry skin conditions.
The global Keratolytic Agents market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Keratolytic Agents is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Keratolytic Agents is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Keratolytic Agents include Pfizer Inc, GSK plc, Novartis AG, Mylan NV, Boehringer Ingelheim International GmbH, AstraZeneca, Johnson & Johnson Private Limited, Bayer AG and Merck & Co., Inc, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Keratolytic Agents, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Keratolytic Agents.
The Keratolytic Agents market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Keratolytic Agents market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Keratolytic Agents manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Pfizer Inc
GSK plc
Novartis AG
Mylan NV
Boehringer Ingelheim International GmbH
AstraZeneca
Johnson & Johnson Private Limited
Bayer AG
Merck & Co., Inc
Bristol-Myers Squibb Company
Cadila Pharmaceuticals
Lilly
LEO Pharma A/S
Cipla Inc
Aurobindo Pharma
Lupin
Sumitomo Corporation
Taro Pharmaceutical Industries Ltd
Segment by Type
Salicylic Acid
Alpha Hydroxy Acid
Azelaic Acid
Tretinoin
Other
Segment by Application
Psoriasis
Acne
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Keratolytic Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Keratolytic Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Keratolytic Agents Market Overview
1.1 Product Overview and Scope of Keratolytic Agents
1.2 Keratolytic Agents Segment by Type
1.2.1 Global Keratolytic Agents Market Value Comparison by Type (2023-2029)
1.2.2 Salicylic Acid
1.2.3 Alpha Hydroxy Acid
1.2.4 Azelaic Acid
1.2.5 Tretinoin
1.2.6 Other
1.3 Keratolytic Agents Segment by Application
1.3.1 Global Keratolytic Agents Market Value by Application: (2023-2029)
1.3.2 Psoriasis
1.3.3 Acne
1.3.4 Other
1.4 Global Keratolytic Agents Market Size Estimates and Forecasts
1.4.1 Global Keratolytic Agents Revenue 2018-2029
1.4.2 Global Keratolytic Agents Sales 2018-2029
1.4.3 Global Keratolytic Agents Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Keratolytic Agents Market Competition by Manufacturers
2.1 Global Keratolytic Agents Sales Market Share by Manufacturers (2018-2023)
2.2 Global Keratolytic Agents Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Keratolytic Agents Average Price by Manufacturers (2018-2023)
2.4 Global Keratolytic Agents Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Keratolytic Agents, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Keratolytic Agents, Product Type & Application
2.7 Keratolytic Agents Market Competitive Situation and Trends
2.7.1 Keratolytic Agents Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Keratolytic Agents Players Market Share by Revenue
2.7.3 Global Keratolytic Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Keratolytic Agents Retrospective Market Scenario by Region
3.1 Global Keratolytic Agents Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Keratolytic Agents Global Keratolytic Agents Sales by Region: 2018-2029
3.2.1 Global Keratolytic Agents Sales by Region: 2018-2023
3.2.2 Global Keratolytic Agents Sales by Region: 2024-2029
3.3 Global Keratolytic Agents Global Keratolytic Agents Revenue by Region: 2018-2029
3.3.1 Global Keratolytic Agents Revenue by Region: 2018-2023
3.3.2 Global Keratolytic Agents Revenue by Region: 2024-2029
3.4 North America Keratolytic Agents Market Facts & Figures by Country
3.4.1 North America Keratolytic Agents Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Keratolytic Agents Sales by Country (2018-2029)
3.4.3 North America Keratolytic Agents Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Keratolytic Agents Market Facts & Figures by Country
3.5.1 Europe Keratolytic Agents Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Keratolytic Agents Sales by Country (2018-2029)
3.5.3 Europe Keratolytic Agents Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Keratolytic Agents Market Facts & Figures by Country
3.6.1 Asia Pacific Keratolytic Agents Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Keratolytic Agents Sales by Country (2018-2029)
3.6.3 Asia Pacific Keratolytic Agents Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Keratolytic Agents Market Facts & Figures by Country
3.7.1 Latin America Keratolytic Agents Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Keratolytic Agents Sales by Country (2018-2029)
3.7.3 Latin America Keratolytic Agents Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Keratolytic Agents Market Facts & Figures by Country
3.8.1 Middle East and Africa Keratolytic Agents Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Keratolytic Agents Sales by Country (2018-2029)
3.8.3 Middle East and Africa Keratolytic Agents Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Keratolytic Agents Sales by Type (2018-2029)
4.1.1 Global Keratolytic Agents Sales by Type (2018-2023)
4.1.2 Global Keratolytic Agents Sales by Type (2024-2029)
4.1.3 Global Keratolytic Agents Sales Market Share by Type (2018-2029)
4.2 Global Keratolytic Agents Revenue by Type (2018-2029)
4.2.1 Global Keratolytic Agents Revenue by Type (2018-2023)
4.2.2 Global Keratolytic Agents Revenue by Type (2024-2029)
4.2.3 Global Keratolytic Agents Revenue Market Share by Type (2018-2029)
4.3 Global Keratolytic Agents Price by Type (2018-2029)
5 Segment by Application
5.1 Global Keratolytic Agents Sales by Application (2018-2029)
5.1.1 Global Keratolytic Agents Sales by Application (2018-2023)
5.1.2 Global Keratolytic Agents Sales by Application (2024-2029)
5.1.3 Global Keratolytic Agents Sales Market Share by Application (2018-2029)
5.2 Global Keratolytic Agents Revenue by Application (2018-2029)
5.2.1 Global Keratolytic Agents Revenue by Application (2018-2023)
5.2.2 Global Keratolytic Agents Revenue by Application (2024-2029)
5.2.3 Global Keratolytic Agents Revenue Market Share by Application (2018-2029)
5.3 Global Keratolytic Agents Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer Inc
6.1.1 Pfizer Inc Corporation Information
6.1.2 Pfizer Inc Description and Business Overview
6.1.3 Pfizer Inc Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Inc Keratolytic Agents Product Portfolio
6.1.5 Pfizer Inc Recent Developments/Updates
6.2 GSK plc
6.2.1 GSK plc Corporation Information
6.2.2 GSK plc Description and Business Overview
6.2.3 GSK plc Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK plc Keratolytic Agents Product Portfolio
6.2.5 GSK plc Recent Developments/Updates
6.3 Novartis AG
6.3.1 Novartis AG Corporation Information
6.3.2 Novartis AG Description and Business Overview
6.3.3 Novartis AG Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Novartis AG Keratolytic Agents Product Portfolio
6.3.5 Novartis AG Recent Developments/Updates
6.4 Mylan NV
6.4.1 Mylan NV Corporation Information
6.4.2 Mylan NV Description and Business Overview
6.4.3 Mylan NV Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Mylan NV Keratolytic Agents Product Portfolio
6.4.5 Mylan NV Recent Developments/Updates
6.5 Boehringer Ingelheim International GmbH
6.5.1 Boehringer Ingelheim International GmbH Corporation Information
6.5.2 Boehringer Ingelheim International GmbH Description and Business Overview
6.5.3 Boehringer Ingelheim International GmbH Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Boehringer Ingelheim International GmbH Keratolytic Agents Product Portfolio
6.5.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.6.4 AstraZeneca Keratolytic Agents Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Johnson & Johnson Private Limited
6.6.1 Johnson & Johnson Private Limited Corporation Information
6.6.2 Johnson & Johnson Private Limited Description and Business Overview
6.6.3 Johnson & Johnson Private Limited Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Johnson & Johnson Private Limited Keratolytic Agents Product Portfolio
6.7.5 Johnson & Johnson Private Limited Recent Developments/Updates
6.8 Bayer AG
6.8.1 Bayer AG Corporation Information
6.8.2 Bayer AG Description and Business Overview
6.8.3 Bayer AG Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bayer AG Keratolytic Agents Product Portfolio
6.8.5 Bayer AG Recent Developments/Updates
6.9 Merck & Co., Inc
6.9.1 Merck & Co., Inc Corporation Information
6.9.2 Merck & Co., Inc Description and Business Overview
6.9.3 Merck & Co., Inc Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Merck & Co., Inc Keratolytic Agents Product Portfolio
6.9.5 Merck & Co., Inc Recent Developments/Updates
6.10 Bristol-Myers Squibb Company
6.10.1 Bristol-Myers Squibb Company Corporation Information
6.10.2 Bristol-Myers Squibb Company Description and Business Overview
6.10.3 Bristol-Myers Squibb Company Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Bristol-Myers Squibb Company Keratolytic Agents Product Portfolio
6.10.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.11 Cadila Pharmaceuticals
6.11.1 Cadila Pharmaceuticals Corporation Information
6.11.2 Cadila Pharmaceuticals Keratolytic Agents Description and Business Overview
6.11.3 Cadila Pharmaceuticals Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Cadila Pharmaceuticals Keratolytic Agents Product Portfolio
6.11.5 Cadila Pharmaceuticals Recent Developments/Updates
6.12 Lilly
6.12.1 Lilly Corporation Information
6.12.2 Lilly Keratolytic Agents Description and Business Overview
6.12.3 Lilly Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Lilly Keratolytic Agents Product Portfolio
6.12.5 Lilly Recent Developments/Updates
6.13 LEO Pharma A/S
6.13.1 LEO Pharma A/S Corporation Information
6.13.2 LEO Pharma A/S Keratolytic Agents Description and Business Overview
6.13.3 LEO Pharma A/S Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.13.4 LEO Pharma A/S Keratolytic Agents Product Portfolio
6.13.5 LEO Pharma A/S Recent Developments/Updates
6.14 Cipla Inc
6.14.1 Cipla Inc Corporation Information
6.14.2 Cipla Inc Keratolytic Agents Description and Business Overview
6.14.3 Cipla Inc Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Cipla Inc Keratolytic Agents Product Portfolio
6.14.5 Cipla Inc Recent Developments/Updates
6.15 Aurobindo Pharma
6.15.1 Aurobindo Pharma Corporation Information
6.15.2 Aurobindo Pharma Keratolytic Agents Description and Business Overview
6.15.3 Aurobindo Pharma Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Aurobindo Pharma Keratolytic Agents Product Portfolio
6.15.5 Aurobindo Pharma Recent Developments/Updates
6.16 Lupin
6.16.1 Lupin Corporation Information
6.16.2 Lupin Keratolytic Agents Description and Business Overview
6.16.3 Lupin Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Lupin Keratolytic Agents Product Portfolio
6.16.5 Lupin Recent Developments/Updates
6.17 Sumitomo Corporation
6.17.1 Sumitomo Corporation Corporation Information
6.17.2 Sumitomo Corporation Keratolytic Agents Description and Business Overview
6.17.3 Sumitomo Corporation Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Sumitomo Corporation Keratolytic Agents Product Portfolio
6.17.5 Sumitomo Corporation Recent Developments/Updates
6.18 Taro Pharmaceutical Industries Ltd
6.18.1 Taro Pharmaceutical Industries Ltd Corporation Information
6.18.2 Taro Pharmaceutical Industries Ltd Keratolytic Agents Description and Business Overview
6.18.3 Taro Pharmaceutical Industries Ltd Keratolytic Agents Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Taro Pharmaceutical Industries Ltd Keratolytic Agents Product Portfolio
6.18.5 Taro Pharmaceutical Industries Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Keratolytic Agents Industry Chain Analysis
7.2 Keratolytic Agents Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Keratolytic Agents Production Mode & Process
7.4 Keratolytic Agents Sales and Marketing
7.4.1 Keratolytic Agents Sales Channels
7.4.2 Keratolytic Agents Distributors
7.5 Keratolytic Agents Customers
8 Keratolytic Agents Market Dynamics
8.1 Keratolytic Agents Industry Trends
8.2 Keratolytic Agents Market Drivers
8.3 Keratolytic Agents Market Challenges
8.4 Keratolytic Agents Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Pfizer Inc
GSK plc
Novartis AG
Mylan NV
Boehringer Ingelheim International GmbH
AstraZeneca
Johnson & Johnson Private Limited
Bayer AG
Merck & Co., Inc
Bristol-Myers Squibb Company
Cadila Pharmaceuticals
Lilly
LEO Pharma A/S
Cipla Inc
Aurobindo Pharma
Lupin
Sumitomo Corporation
Taro Pharmaceutical Industries Ltd

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂